Mercury Biopharmaceutical Corporation (TPEX:6932)
Taiwan
· Delayed Price · Currency is TWD 15.10
+0.60 (4.14%)
Apr 2, 2025, 2:59 PM CST
Mercury Biopharmaceutical Revenue
Mercury Biopharmaceutical had revenue of 4.72M TWD in the half year ending June 30, 2024. This brings the company's revenue in the last twelve months to 5.75M, up 114.55% year-over-year. In the year 2023, Mercury Biopharmaceutical had annual revenue of 1.03M, down -61.46%.
Revenue (ttm)
5.75M
Revenue Growth
+114.55%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
6.12B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 1.03M | -1.65M | -61.46% |
| Dec 31, 2022 | 2.68M | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PharmaEssentia | 9.73B |
| Caliway Biopharmaceuticals | 44.43M |
| Bora Pharmaceuticals Co., LTD. | 19.25B |
| Lotus Pharmaceutical | 18.58B |
| Oneness Biotech | 117.93M |
| Lumosa Therapeutics | 39.15M |
| Pegavision | 6.82B |
| Polaris Group | 107.00M |